CoChat

Phase 1 Trial of Antibody NI006 for Depletion of Cardiac Transthyretin Amyloid

Open access
Garcia-Pavia, Pablo, aus dem Siepen, Fabian, Donal, Erwan, Lairez, Olivier, van der Meer, Peter, Kristen, Arnt V., Mercuri, Michele F., Michalon, Aubin, Frost, Robert J.A., Grimm, Jan, Nitsch, Roger M., Hock, Christoph, Kahr, Peter C., Damy, Thibaud · 2023 · New England Journal of Medicine
Cited by 248

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Abstract

BACKGROUND: Transthyretin amyloid (ATTR) cardiomyopathy is a progressive and fatal disease caused by misfolded transthyretin. Despite advances in slowing disease progression, there is no available treatment that depletes ATTR from the heart for the amelioration of cardiac dysfunction. NI006 is a recombinant human anti-ATTR antibody that was developed for the removal of ATTR by phagocytic immune cells. METHODS: In this phase 1, double-blind trial, we randomly assigned (in a 2:1 ratio) 40 patients with wild-type or variant ATTR cardiomyopathy and chronic heart failure to receive intravenous infusions of either NI006 or placebo every 4 weeks for 4 months. Patients were sequentially enrolled in six cohorts that received ascending doses (ranging from 0.3 to 60 mg per kilogram of body weight). After four infusions, patients were enrolled in an open-label extension phase in which they received eight infusions of NI006 with stepwise increases in the dose. The safety and pharmacokinetic profiles of NI006 were assessed, and cardiac imaging studies were performed. RESULTS: The use of NI006 was associated with no apparent drug-related serious adverse events. The pharmacokinetic profile of NI006 was consistent with that of an IgG antibody, and no antidrug antibodies were detected. At doses of at least 10 mg per kilogram, cardiac tracer uptake on scintigraphy and extracellular volume on cardiac magnetic resonance imaging, both of which are imaging-based surrogate markers of cardiac amyloid load, appeared to be reduced over a period of 12 months. The median N-terminal pro-B-type natriuretic peptide and troponin T levels also seemed to be reduced. CONCLUSIONS: In this phase 1 trial of the recombinant human antibody NI006 for the treatment of patients with ATTR cardiomyopathy and heart failure, the use of NI006 was associated with no apparent drug-related serious adverse events. (Funded by Neurimmune; NI006-101 ClinicalTrials.gov number, NCT04360434.).

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1056/nejmoa2303765

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 4 references

Cited by

See all 248

Metadata

Authors
Garcia-Pavia, P., aus dem Siepen, F., Donal, E., Lairez, O., van der Meer, P., Kristen, A. V., Mercuri, M. F., Michalon, A., Frost, R. J. A., Grimm, J., Nitsch, R. M., Hock, C., Kahr, P. C., & Damy, T.
Venue
New England Journal of Medicine
Published
2023-07-20
Volume
389
Issue
3
Pages
239-250
ISSN
  • 0028-4793 (ISSN-L)
  • 1533-4406
OpenAlex
W4377137084
Cited by
248
References
4
FWCI
18.46
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Phase 1 Trial of Antibody NI006 for Depletion of Cardiac Transthyretin Amyloid. https://app.cochat.ai/papers/10.1056/nejmoa2303765
The paper
Garcia-Pavia, P., aus dem Siepen, F., Donal, E., Lairez, O., van der Meer, P., Kristen, A. V., Mercuri, M. F., Michalon, A., Frost, R. J. A., Grimm, J., Nitsch, R. M., Hock, C., Kahr, P. C., & Damy, T. (2023). Phase 1 Trial of Antibody NI006 for Depletion of Cardiac Transthyretin Amyloid. New England Journal of Medicine. https://doi.org/10.1056/nejmoa2303765

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.